Stezza, read below screenshot from EMV announcement on 27/3/25. “Data will be collected from these participants in a way that allows sequential validation of additional features such as ischemia detection without undertaking an additional full validation trial.”
Important to note, all data acquired in the parallel continuous innovation trial will be used as training data to refine and improve algorithms. The algorithms will then be applied to the 300 Pivotal Trial scans at completion.
Ann: Enhanced Algorithm Performance From Continuous Innovation, page-13
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
-0.045(2.45%) |
Mkt cap ! $153.0M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.85 | $1.72 | $127.4K | 72.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8620 | $1.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| EMV (ASX) Chart |